News

VitalStream Offers Continuous Hemodynamic Monitoring Solution Amid IV Fluid Shortage

Caretaker Medical, a pioneer in advanced hemodynamic monitoring technology, is highlighting the critical role of its VitalStream solution in addressing the ongoing IV fluid shortage caused by Hurricane Helene. As healthcare providers face challenges in maintaining continuous blood pressure monitoring due to the limited availability of Baxter IV fluids, VitalStream offers a reliable and innovative alternative.

VitalStream provides continuous hemodynamic monitoring without the need for invasive arterial lines or continuous IV fluid infusion. This groundbreaking technology eliminates the reliance on IV fluids for blood pressure measurement, offering significant advantages during times of supply shortages. By providing real-time insights into a patient’s response to fluids, VitalStream can potentially reduce the overall need for IV fluid administration.

“The IV fluid shortage has created a significant challenge for healthcare providers across the country,” said Johnny Mann, VP Sales and Marketing at Caretaker Medical. “VitalStream offers a valuable solution by enabling continuous hemodynamic monitoring without the need for invasive lines or constant IV fluid infusion. This technology can help ensure patient safety and optimize fluid management during these challenging times.”

Caretaker Medical will be showcasing VitalStream at the upcoming American Society of Anesthesiologists (ASA) Conference in Philadelphia from October 19-21. Attendees will have the opportunity to learn more about this innovative technology and its potential benefits in addressing the current IV fluid shortage.

Learn more here.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and